Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action - PubMed (original) (raw)

Clinical Trial

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

F X Vollenweider et al. Neuroreport. 1998.

Abstract

Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to serotonin-2A receptor activation, independently of dopamine stimulation. Thus, serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics.

PubMed Disclaimer

Similar articles

• Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.
  Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Kometer M, et al. J Neurosci. 2013 Jun 19;33(25):10544-51. doi: 10.1523/JNEUROSCI.3007-12.2013. J Neurosci. 2013. PMID: 23785166 Free PMC article. Clinical Trial.
• Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.
  Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Quednow BB, et al. Neuropsychopharmacology. 2012 Feb;37(3):630-40. doi: 10.1038/npp.2011.228. Epub 2011 Sep 28. Neuropsychopharmacology. 2012. PMID: 21956447 Free PMC article. Clinical Trial.
• Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.
  Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Carter OL, et al. J Cogn Neurosci. 2005 Oct;17(10):1497-508. doi: 10.1162/089892905774597191. J Cogn Neurosci. 2005. PMID: 16269092 Clinical Trial.
• The role of serotonin receptors in the action of atypical antipsychotic drugs.
  Meltzer HY, Massey BW. Meltzer HY, et al. Curr Opin Pharmacol. 2011 Feb;11(1):59-67. doi: 10.1016/j.coph.2011.02.007. Epub 2011 Mar 21. Curr Opin Pharmacol. 2011. PMID: 21420906 Review.
• [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
  Jastrzebski M, Bala A. Jastrzebski M, et al. Psychiatr Pol. 2013 Nov-Dec;47(6):1157-67. Psychiatr Pol. 2013. PMID: 25007546 Review. Polish.

Cited by

• Body mass index (BMI) does not predict responses to psilocybin.
  Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL. Spriggs MJ, et al. J Psychopharmacol. 2023 Jan;37(1):107-116. doi: 10.1177/02698811221131994. Epub 2022 Nov 14. J Psychopharmacol. 2023. PMID: 36373934 Free PMC article.
• Restructuring consciousness -the psychedelic state in light of integrated information theory.
  Gallimore AR. Gallimore AR. Front Hum Neurosci. 2015 Jun 12;9:346. doi: 10.3389/fnhum.2015.00346. eCollection 2015. Front Hum Neurosci. 2015. PMID: 26124719 Free PMC article.
• Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms.
  Patocka J, Wu R, Nepovimova E, Valis M, Wu W, Kuca K. Patocka J, et al. Int J Mol Sci. 2021 Feb 23;22(4):2218. doi: 10.3390/ijms22042218. Int J Mol Sci. 2021. PMID: 33672330 Free PMC article. Review.
• Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential.
  Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD. Wallach J, et al. Nat Commun. 2023 Dec 15;14(1):8221. doi: 10.1038/s41467-023-44016-1. Nat Commun. 2023. PMID: 38102107 Free PMC article.
• Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex.
  Béïque JC, Imad M, Mladenovic L, Gingrich JA, Andrade R. Béïque JC, et al. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9870-5. doi: 10.1073/pnas.0700436104. Epub 2007 May 29. Proc Natl Acad Sci U S A. 2007. PMID: 17535909 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information